Table S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Co-targeting of bcl-xl and mcl-1 shows synergistic effects in AR-V7-expressing CRPC models, which enhances treatment efficacy.
• IC50 values for BH3 mimetics identified in Table S2 indicate their activity as single agents in both 2D culture and 3D spheroids.
• Assessment of drug interactions aligns with methods comparing impact across different cellular models, demonstrating effectiveness.
• Clinical implications arise for future CRPC therapies, as targeting both proteins may improve patient outcomes in prostate cancer.